A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-09-30

Study Completion Date

2006-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical research study is to evaluate if Aripiprazole will prove to be effective, safe and well tolerated in the treatment of patients with schizophrenia who are treated in a general psychiatric setting.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aripiprazole

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical DSM-IV diagnosis of schizophrenia
* Patients being managed as outpatients, for whom an alteration in medication is clinically reasonable or initiation of antipsychotics is required

Exclusion Criteria

* Risk of committing suicide, diagnosis of schizoaffective disorder, bipolar disorder, depression with psychotic syptoms, or organic brain syndromes
* Prisoners or subjects compulsory detained

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hervé Allain, MD

Role: PRINCIPAL_INVESTIGATOR

Faculté de Médecine de Rennes I, laboratoire de pharmacologie

Review additional registry numbers or institutional identifiers associated with this trial.

CN138-100

Identifier Type: -

Identifier Source: org_study_id

A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Study Design

Interventions

Aripiprazole

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Otsuka America Pharmaceutical

Otsuka Pharmaceutical Development & Commercialization, Inc.

Principal Investigators

Hervé Allain, MD

Locations

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Local Institution

Countries

Other Identifiers

CN138-100